SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Procyon Biopharma Inc.

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: thebeach who wrote (306)3/6/2001 2:07:06 PM
From: thebeach  Read Replies (1) of 356
 
PROCYON BIOPHARMA INC - Retains Investor Relations Firm - Renmark Financial Communications [222]

Canadian Market News from Market News Publishing, Tuesday, March 06, 2001 at 10:13

Procyon BioPharma Inc. ("Procyon") announced that is has retained the
services of Renmark Financial Communications Inc. ("Renmark") as their
investor relations ("IR") firm, a well known IR firm located in Montreal,
Quebec .
"We are pleased to announce that Renmark has been chosen to
enhance our investor relations function. We believe that Renmark
will provide Procyon increased visibility within the financial
community by providing our Company with an effective investor
relations program," stated Hans J. Mader, President and CEO of
Procyon.
In consideration of the services to be provided, the Company has
agreed to pay a monthly retainer to Renmark Financial
Communications. In addition, subject to approval from applicable
regulatory authorities, the Company has agreed to grant to Renmark
stock options to acquire common shares of Procyon.
Procyon BioPharma Inc. is a publicly listed, biopharmaceutical
Company focused principally on advancing two powerful platform
technologies that have the potential to diagnose and treat cancer.
Procyon's non-pathogenic Antinuclear Autoantibodies (ANAs) bind
specifically to multiple cancer cell types strongly enhancing the
immune response to cancer cells. Prostate Secretory Protein
PSP(94) is a naturally occurring human protein that has the
potential to treat prostate cancer by inhibiting abnormal prostate
cell growth. In addition, the estimation of PSP(94) levels in
prostate cancer patients may have prognostic and diagnostic
applications. Procyon also has two late-stage products:
FIBROSTAT(TM) and COLOPATH(TM) a rapid, non-invasive screening
test for colorectal cancer.
Procyon's shares trade on the Toronto Stock Exchange under the
ticker symbol PBP.

TEL: (514)-685-9283 Procyon BioPharma Inc.
Hans Mader, President & CEO
EMAIL: hmader@procyonbiopharma.com
INET : www.procyonbiopharma.com
TEL: (514)-843-2309 NATIONAL Public Relations
Nathalie Bourque (Public Relations)

TEL: (514) 939-3989 Renmark Financial Communications Inc.
John Stella (Investors Relations)
EMAIL: jstella@renmarkfinancial.com
INET : www.renmarkfinancial.com

TEL: (514) 939-3989 Renmark Financial Communications Inc.
John Boidman (Investors Relations)
EMAIL: jboidman@renmarkfinancial.com
INET : www.renmarkfinancial.com

(c) Market News Publishing Inc. Tel:(604) 689-1101
All rights reserved. Fax:(604) 689-1106
MarketbyFax(tm) - To get the NEWS as it happens, call (604) 689-3041.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext